Compare ProShares Ultra Silver ETF (AGQ) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Charles River Laboratories Intl. Inc — how do they compare? ProShares Ultra Silver ETF trades at $64.62, while Charles River Laboratories Intl. Inc trades at $221.72 (market cap $11.01B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | CRL | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $231.43 |
52-Week Low | $48.15 | $145.57 |
Market Cap | — | $11.01B |
Enterprise Value | — | $13.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
CRL trades at $228.68, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported negative net income of -$144.34M in 2025 despite revenue stability around $4.02B, resulting in a high P/E of 684.85. Recent earnings beats and strategic collaborations, such as with Lilly TuneLab (Business Wire, 2026-06-18), highlight operational strengths amid profitability challenges.
Outlook is mixed: strong analyst support (72% buy ratings) and positive cash flow trends contrast with negative margins and high debt. Key risks include sustained unprofitability and competitive pressures, but institutional confidence and technical momentum suggest potential for recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
